Literature DB >> 15041804

Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome.

Benoit Coffin1, Michel Dapoigny, Denis Cloarec, Denis Comet, François Dyard.   

Abstract

AIMS: Heath-related quality of life (QoL) is decreased in patients with irritable bowel syndrome (IBS) but the relationship between symptom intensity of IBS and QoL remains largely unknown. The aim of this prospective survey was to investigate the relationship between intensity of IBS and changes in QoL.
METHODS: Eight hundred and fifty-eight patients with IBS, according to Rome II criteria, completed a symptom questionnaire to measure intensity of IBS, and the gastrointestinal quality of life (GIQLI) questionnaire, which is a general QoL measure in patients with gastrointestinal disorders.
RESULTS: 37.2% of the patients had constipation-predominant type IBS, 37.3% had diarrhea-predominant IBS and 25.4% had alternating diarrhea and constipation type symptoms. IBS was considered to be in remission or mild in 8.3% of patients; 41.3% had moderate IBS and 50.4% had severe IBS. The mean GIQLI score was 88 +/- 20. There was a significant correlation between symptom intensity and changes in QoL. Other significantly related factors were the type of bowel abnormality and gender.
CONCLUSION: In IBS patients, symptom intensity and type of IBS have a negative impact on health-related QoL.

Entities:  

Mesh:

Year:  2004        PMID: 15041804     DOI: 10.1016/s0399-8320(04)94834-8

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  20 in total

Review 1.  Diagnosis and management of IBS.

Authors:  Sarah Khan; Lin Chang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10       Impact factor: 46.802

2.  I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.

Authors:  Vicente Lorenzo-Zúñiga; Elba Llop; Cristina Suárez; Beatriz Alvarez; Luis Abreu; Jordi Espadaler; Jordi Serra
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Latent structure of irritable bowel syndrome symptom severity.

Authors:  Fabian Jasper; Boris Egloff; Andrea Roalfe; Michael Witthöft
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

4.  Meta-analysis: do irritable bowel syndrome symptoms vary between men and women?

Authors:  M A Adeyemo; B M R Spiegel; L Chang
Journal:  Aliment Pharmacol Ther       Date:  2010-07-22       Impact factor: 8.171

Review 5.  New treatments for irritable bowel syndrome in women.

Authors:  Mopelola A Adeyemo; Lin Chang
Journal:  Womens Health (Lond)       Date:  2008-11

6.  Irritable bowel syndrome: diagnosis and pathogenesis.

Authors:  Magdy El-Salhy
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

Review 7.  Is irritable bowel syndrome an organic disorder?

Authors:  Magdy El-Salhy; Doris Gundersen; Odd Helge Gilja; Jan Gunnar Hatlebakk; Trygve Hausken
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

8.  Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with irritable bowel syndrome.

Authors:  J-M Sabate; M Veyrac; F Mion; L Siproudhis; P Ducrotte; F Zerbib; J-C Grimaud; M Dapoigny; F Dyard; B Coffin
Journal:  Aliment Pharmacol Ther       Date:  2008-06-09       Impact factor: 8.171

9.  Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study.

Authors:  Michel Dapoigny; Thierry Piche; Philippe Ducrotte; Bernard Lunaud; Jean-Michel Cardot; Annick Bernalier-Donadille
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

10.  Factorial study of moxibustion in treatment of diarrhea-predominant irritable bowel syndrome.

Authors:  Ji-Meng Zhao; Lu-Yi Wu; Hui-Rong Liu; Hong-Yi Hu; Jia-Ying Wang; Ren-Jia Huang; Yin Shi; Shan-Ping Tao; Qiang Gao; Ci-Li Zhou; Li Qi; Xiao-Peng Ma; Huan-Gan Wu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.